Table 1.

Chimerism and relapse data of 22 patients relapsed after Haplo-HSCT with PTCy.

Patient	Diagnosis	Chimerism at HLA-loss study (% Recipient)†	Sample type	Relapse details (MRD (Flow cytometry and genetic) and imaging evaluation)			HLA-loss relapse	Exitus
1	DCL	5	BM	30% blasts	MRD +		Yes	Yes
2	AML	1.6	BM	CNS infiltration	MRD +	WT1 +	Yes	Yes
3	MDS	1.5	BM	7% blasts	WT1 +		Yes	Yes
4	HL	26	Pelvic adenopathy	Mediastinal adenopathy	PET/CT positive		Yes	Yes
5	HL	13.6	Axillary adenopathy	Supra/infradiaphragmatic relapse	PET/CT positive		Yes	No
6	ALL-T	11	PB	17% blasts	MRD +		Yes	Yes
7	AML	23	PB	24% blasts	MRD +	WT1 +	No	Yes
8	NHL	2.5	BM	BM infiltration 25% blasts. Axillary and mediastinal adenophaty	MRD +	PET/CT positive	No	Yes
9	NHL	38	Hepatic adenopathy	Liver infiltration	PET/CT positive		No	Yes
10	ALL-B	7.8	PB	60% blasts	MRD +		No	Yes
11	NHL	44	BM	CNS + BM infiltration 25% blasts	MRD +		No	Yes
12	AML	12	PB	28% blasts	MRD +	FLT3 /WT1 +	No	No
13	AML	88	PB	90% blasts	MRD +	NPM1/WT1 +	No	Yes
14	ALL-B	24	BM	Mediastinal adenopathy. CNS + BM 5% infiltration	MRD +	PET/CT positive	No	Yes
15	ALL-B	1.5	PB	62% blasts	MRD +		No	Yes
16	AML	1.6	BM	10% blasts	MRD +	WT1 +	No	No
17	AML	31	BM	46% blasts	MRD +	WT1 +	No	Yes
18	AML	20.6	BM	25% blasts	MRD +	WT1 +	No	Yes
19	AML secondary to NHL	97	PB	90% blasts	MRD +	WT1 +	No	Yes
20	HL	22	Cervical adenopathy	Cervical adenopathy	PET/CT positive		No	Yes
21	AML	76	PB	Medullary aplasia	FLT3/NPM1 +		No	Yes
22	AML	90	BM	86% blasts	MRD +		No	Yes

ALL-B, B-cell acute lymphoblastic leukemia; ALL-T, T-cell acute lymphoblastic leukemia; AML, acute myeloid leukemia; CNS, central nervous system; CSF, cerebrospinal fluid; DCL, dendritic cell leukemia; GVHD, graft-vs.-host disease; HL, hodgkin's lymphoma; HSCT, hematopoietic stem cell transplantation; MRD, minimal residual disease; MDS, myelodysplastic syndrome; NHL, non-hodgkin's lymphoma. MRD +, MRD positive; WT1+, overexpression WT1.

^†Post-transplantation hematopoietic chimerism was evaluated using short tandem repeat. PET/CT was employed for study relapsed patients with lymphoproliferative syndrome without bone marrow infiltration.